Effect of Evolocumab on Coronary Plaque Characteristics
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 137 participants.
Also called NCT04710368
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose basic science
- Phase
- Phase 4
- Enrolled
- 137 participants
- Sponsor
- Annapoorna Kini
- Registry
-
NCT04710368
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04710368. Allocation not applicable; no masking; primary purpose basic science. Start 2021-05-04 (actual); primary completion 2022-10-28 (actual). Results posted on 2023-05-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Evolocumab on Coronary Plaque Characteristics
- Acronym
- YELLOW III
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Evolocumab Injections
- Lead sponsor
- Annapoorna Kini
Record details
- Record id
cardio:ct-nct04710368- Content hash
179c70ee9065b9fe56d821ed9ca304f8a41dd5483781a15f4b0bd1835832d5a2